Gilead Sciences, Inc. $GILD Holdings Boosted by CI Investments Inc.

CI Investments Inc. boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 119.8% in the first quarter, HoldingsChannel reports. The firm owned 224,299 shares of the biopharmaceutical company’s stock after purchasing an additional 122,233 shares during the quarter. CI Investments Inc.’s holdings in Gilead Sciences were worth $31,261,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. First Trust Advisors LP increased its stake in shares of Gilead Sciences by 116.4% in the first quarter. First Trust Advisors LP now owns 3,129,637 shares of the biopharmaceutical company’s stock valued at $436,177,000 after purchasing an additional 1,683,586 shares during the period. Millennium Capital Advisors LLC bought a new position in Gilead Sciences in the 1st quarter worth approximately $216,000. CacheTech Inc. grew its holdings in Gilead Sciences by 4.4% in the 1st quarter. CacheTech Inc. now owns 7,217 shares of the biopharmaceutical company’s stock worth $1,006,000 after buying an additional 303 shares in the last quarter. Meiji Yasuda America Inc increased its position in Gilead Sciences by 22.1% in the 1st quarter. Meiji Yasuda America Inc now owns 30,454 shares of the biopharmaceutical company’s stock valued at $4,244,000 after acquiring an additional 5,520 shares during the period. Finally, PNC Financial Services Group Inc. increased its holdings in shares of Gilead Sciences by 2.6% during the first quarter. PNC Financial Services Group Inc. now owns 486,271 shares of the biopharmaceutical company’s stock valued at $67,772,000 after purchasing an additional 12,166 shares during the period. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In other news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $131.29, for a total value of $3,676,120.00. Following the transaction, the insider directly owned 125,779 shares in the company, valued at approximately $16,513,524.91. The trade was a 18.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $126.29, for a total value of $1,894,350.00. Following the completion of the transaction, the chief executive officer directly owned 607,133 shares in the company, valued at approximately $76,674,826.57. This represents a 2.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 77,000 shares of company stock worth $9,978,740 in the last quarter. 0.30% of the stock is currently owned by company insiders.

Gilead Sciences Trading Up 0.0%

Shares of NASDAQ:GILD opened at $130.34 on Thursday. The stock has a market capitalization of $161.83 billion, a PE ratio of 17.76 and a beta of 0.32. The firm has a fifty day moving average price of $129.58 and a 200 day moving average price of $135.47. Gilead Sciences, Inc. has a 1 year low of $108.46 and a 1 year high of $157.29. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.12. The firm had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The company’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period in the previous year, the company earned $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Analysts expect that Gilead Sciences, Inc. will post -0.77 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, June 29th. Investors of record on Monday, June 15th were paid a $0.82 dividend. The ex-dividend date was Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead and Merck reported that their experimental once-weekly HIV pill kept the virus suppressed in two late-stage trials, a key step that supports upcoming regulatory filings and could position the regimen as a first-of-its-kind treatment. Article Title
• Positive Sentiment: Gilead said it will present new HIV research at AIDS 2026, including long-term efficacy and safety data for lenacapavir and results from its collaboration with Merck, reinforcing investor attention on its HIV franchise. Article Title
• Positive Sentiment: Gilead advanced a long-acting HIV regimen into a new Phase 3 head-to-head trial, signaling continued pipeline progress in one of the company’s most important growth areas. Article Title
• Neutral Sentiment: Gilead announced it will release second-quarter 2026 results on August 4, which keeps the stock in focus but does not provide new financial information yet. Article Title
• Neutral Sentiment: Market coverage noted that Gilead was trending and underperforming some peers intraday, suggesting mixed trading sentiment rather than a clear company-specific shock. Article Title
• Negative Sentiment: Leerink Partners downgraded Gilead to “market perform” from “outperform” and cut its price target to $127 from $146, which may be weighing on the shares. Article Title

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Weiss Ratings cut Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, May 28th. Truist Financial dropped their price target on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $155.00 target price on shares of Gilead Sciences in a report on Monday, July 6th. Daiwa Securities Group lowered their price target on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday, May 19th. Finally, Leerink Partners lowered shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $146.00 to $127.00 in a research report on Tuesday. Twenty-five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $158.33.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.